A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
Primary Purpose
Narcolepsy
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
JNJ-17216498
JNJ-17216498
Modafinil
Sponsored by
About this trial
This is an interventional treatment trial for Narcolepsy focused on measuring narcolepsy, sleepiness
Eligibility Criteria
Inclusion Criteria:
- diagnosis of narcolepsy within the past 5 years
- good general health
- no history or presence of drug or alcohol abuse
Exclusion Criteria:
- current use of prescription or over the counter medications including asprin or herbal supplements with the exception of acetaminophen (Tylenol)
- use of fluoxetine (Prozac) in the past 6 weeks
- use of Xyrem in the past 4 weeks
- use of tobacco products in the past 3 months
- caffeine consumption that is more than 5 cups of tea, or 3 cups of coffee or 8 cans of soda per day
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
001
002
003
Arm Description
JNJ-17216498 10mg one time
JNJ-17216498 50mg one time
Modafinil 200 mg X 2
Outcomes
Primary Outcome Measures
Explore the effectiveness of JNJ-17216498 in patients with narcolepsy as determined by the Maintenance of Wakefulness Test done throughout the study.
Secondary Outcome Measures
Explore the safety and tolerability of JNJ-17216498 in patients with narcolepsy by assessing adverse events, vital signs, laboratory results, vision tests, physical exam and ECGs.
Full Information
NCT ID
NCT00424931
First Posted
January 19, 2007
Last Updated
May 21, 2014
Sponsor
Alza Corporation, DE, USA
1. Study Identification
Unique Protocol Identification Number
NCT00424931
Brief Title
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
Official Title
A Phase II Randomized, Double-blind, Double-dummy, Placebo and Comparator-controlled, Parallel Group, Multi-Center Study to Investigate the Safety and Efficacy of a Single Dose of JNJ-17216498 Administered to Subjects With Narcolepsy.
Study Type
Interventional
2. Study Status
Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
January 2007 (undefined)
Primary Completion Date
November 2007 (Actual)
Study Completion Date
December 2007 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alza Corporation, DE, USA
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to evaluate the safety and effectiveness of JNJ-17216498 compared to modafinil and placebo in patients with narcolepsy, with and without cataplexy.
Detailed Description
This study with a new, experimental drug is being done to assess safety and tolerability, and to explore effectiveness in the treatment of narcolepsy. Approximately 64 adult patients with narcolepsy with or without cataplexy will be recruited for the study. Patients who meet study criteria will need to stop taking their current narcolepsy and/ or other medication for at least 14 days before checking into the site for 3 nights. They will be randomly assigned to one of 4 treatment arms; each patient has an equal chance of receiving placebo, 10 mg JNJ-17216498, 50 mg JNJ-17216498 or 400 mg modafinil. Placebo has no active drug. Modafinil is a drug currently approved to treat narcolepsy. Patients will take the medication on only one day and will receive study medication in a blinded fashion, i.e. the patient, the doctor and the study sponsor will not know what group the patient is in until all patients complete the study. The investigator and the sponsor will monitor the study for the occurrence of possible side effects. In addition to a screening visit and the three nights at the site, there will be a follow-up visit 7-10 days after the day the study drug is taken. After the follow-up visit, patients may resume their previous narcolepsy medications. Medical history, physical examination, vision tests, blood pressure, heart rate, temperature, and ECGs will be checked periodically. Blood samples will be taken for standard safety laboratory tests as well as for the measurement of the drug blood level. The Maintenance of Wakefulness Test will be done to assess the patient's ability to resist falling asleep while reclining in a dark, quiet room; this will involve completing 7 sessions before dosing and 10 sessions after dosing. Patients will have two polysomnograms, a test of brain, muscle and eye activity during sleep, obtained by recording brain waves and other activities such as muscle and eye movement. Polysomnograms will be obtained overnight, once before and once after dosing. Patients will also complete brief questionnaires about their sleepiness and the status of their narcolepsy throughout the study. Patients will receive capsules containing either 10 mg JNJ-17216498, 50 mg JNJ-17216498, 400 mg modafinil and/or placebo on one day. Seven capsules will be taken orally in the morning and two capsules will be taken orally in the afternoon. Placebo contains no active drug. Modafinil is a drug currently approved to treat narcolepsy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Narcolepsy
Keywords
narcolepsy, sleepiness
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
001
Arm Type
Experimental
Arm Description
JNJ-17216498 10mg one time
Arm Title
002
Arm Type
Experimental
Arm Description
JNJ-17216498 50mg one time
Arm Title
003
Arm Type
Active Comparator
Arm Description
Modafinil 200 mg X 2
Intervention Type
Drug
Intervention Name(s)
JNJ-17216498
Intervention Description
50mg one time
Intervention Type
Drug
Intervention Name(s)
JNJ-17216498
Intervention Description
10mg one time
Intervention Type
Drug
Intervention Name(s)
Modafinil
Intervention Description
200 mg X 2
Primary Outcome Measure Information:
Title
Explore the effectiveness of JNJ-17216498 in patients with narcolepsy as determined by the Maintenance of Wakefulness Test done throughout the study.
Time Frame
·To explore efficacy of JNJ-17216498 in patients with narcolepsy with or without cataplexy up through 48 hours after dosing.
Secondary Outcome Measure Information:
Title
Explore the safety and tolerability of JNJ-17216498 in patients with narcolepsy by assessing adverse events, vital signs, laboratory results, vision tests, physical exam and ECGs.
Time Frame
To explore the safety and tolerability of JNJ-17216498 in patients with narcolepsy with or without cataplexy throughout the study.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
diagnosis of narcolepsy within the past 5 years
good general health
no history or presence of drug or alcohol abuse
Exclusion Criteria:
current use of prescription or over the counter medications including asprin or herbal supplements with the exception of acetaminophen (Tylenol)
use of fluoxetine (Prozac) in the past 6 weeks
use of Xyrem in the past 4 weeks
use of tobacco products in the past 3 months
caffeine consumption that is more than 5 cups of tea, or 3 cups of coffee or 8 cans of soda per day
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alza Corporation Clinical Trial
Organizational Affiliation
ALZA
Official's Role
Study Director
Facility Information:
City
Birmingham
State/Province
Alabama
Country
United States
City
Phoenix
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
San Diego
State/Province
California
Country
United States
City
Stanford
State/Province
California
Country
United States
City
Spring Hill
State/Province
Florida
Country
United States
City
St Petersburg
State/Province
Florida
Country
United States
City
Macon
State/Province
Georgia
Country
United States
City
Danville
State/Province
Indiana
Country
United States
City
Fort Wayne
State/Province
Indiana
Country
United States
City
Amherst
State/Province
New York
Country
United States
City
Cincinnati
State/Province
Ohio
Country
United States
City
Toledo
State/Province
Ohio
Country
United States
City
Columbia
State/Province
South Carolina
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Spokane
State/Province
Washington
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Safety and Effectiveness Study of a Single Dose of JNJ-17216498 in Patients With Narcolepsy
We'll reach out to this number within 24 hrs